18LBA A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients

2009 ◽  
Vol 7 (3) ◽  
pp. 11 ◽  
Author(s):  
P. Vasey ◽  
R. Largillier ◽  
M. Gropp ◽  
V. Gebski ◽  
R. Sandvei ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Phase Iii ◽  
Platinum Sensitive ◽  
Phase Iii Study

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5509-LBA5509
Author(s):  
E. Pujade-Lauraine ◽  
S. Mahner ◽  
J. Kaern ◽  
V. Gebski ◽  
M. Heywood ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Liposomal Doxorubicin ◽  
Gynecologic Cancer ◽  
Pegylated Liposomal Doxorubicin ◽  
Phase Iii ◽  
Platinum Sensitive ◽  
Phase Iii Study ◽  
Final Text

LBA5509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document